JPS5874615A - Composition for cancer treatment - Google Patents

Composition for cancer treatment

Info

Publication number
JPS5874615A
JPS5874615A JP56174406A JP17440681A JPS5874615A JP S5874615 A JPS5874615 A JP S5874615A JP 56174406 A JP56174406 A JP 56174406A JP 17440681 A JP17440681 A JP 17440681A JP S5874615 A JPS5874615 A JP S5874615A
Authority
JP
Japan
Prior art keywords
tissue
cancer
cells
brain tissue
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP56174406A
Other languages
Japanese (ja)
Inventor
ダニエル・マルバン−ド・ラ・トレ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JPS5874615A publication Critical patent/JPS5874615A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。
(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.

Description

【発明の詳細な説明】 本発明線、癌治療に関するものであシ、さらに詳しくは
、あらゆる進展段階の癌腫を退縮させるのに有益な癌治
療用の組成物と方法に関するものである。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to cancer therapy, and more particularly to compositions and methods for cancer therapy that are useful in regressing carcinomas at all stages of development.

近年、′癌は放射線、微量の毒性化学薬品、ウィルス、
宜九線細胞の遺伝メツセージの転写にお亀た2ンダム・
エラーなどが引・金となって、身体を形成する無数の細
胞の中の九だ一つに始まることが完全に暑識された。
In recent years, cancer has been treated with radiation, small amounts of toxic chemicals, viruses,
Two random effects on the transcription of genetic messages in Yikyusen cells.
I became completely aware that an error can be a trigger, starting with every single one of the countless cells that make up the body.

外的または内的影響に・よ如ひと九び細胞の遺伝メツセ
ージが変わると、細胞は分裂を開始し、正常な遺伝的拘
束に反して異常細胞を形成する。一方、平常はあらゆる
タイプの異質細胞にも油断なく気を配っている身体の免
疫システム拡止しい応答をしなくな)、その防御単位は
侵入細胞に対する攻撃中破壊活動を止めてしまう。損傷
を回復した後の繁殖ま九は正常な発育を停止し九健康愈
細胞と異なり、異常細胞(癌細胞)は、分裂領域に境界
線がないため、広範にわたつ1成長を続け、増大する塊
シを九は腫瘍を形成しながら健康な組織へ拡張し、正常
細胞と栄養の奪い合いをする。またこの悪性細胞は、血
流あるい社りyパ系へ移行し、そこから体全体へと運ば
れてゆく・このようにしていわゆる転移と呼ばれるもの
が作られるのである。
When an external or internal influence alters the genetic message of a cell, the cell begins to divide, defying its normal genetic constraints and forming abnormal cells. Meanwhile, the body's immune system, which is normally on the lookout for foreign cells of all types, does not respond extensively), and its defense units halt their destructive activities during attacks on invading cells. After the damage has been repaired, reproductive cells cease to develop normally, and unlike healthy cells, abnormal cells (cancer cells) continue to grow over a wide range of areas and increase in size because their division regions do not have boundaries. While forming a tumor, the tumor expands into healthy tissue and competes with normal cells for nutrients. These malignant cells also move into the bloodstream or the lymphatic system, and from there are carried throughout the body, creating what is called a metastasis.

蟲諌技術分野で働く者は通例、炭化した細胞の遺伝メツ
セージな元に戻すことができ九ら癌の形成を阻止できる
のではないかと強く感じている。だが今日までそのよう
な復元を行う手段はまり九〈考案されてしない。従りて
、広く一般に行われ最良と見做されている癌治療唸、不
愉快で衰弱畜せることが多く時には外形を損う治療、す
なわち外科、放射線および化学療法という3種O組合せ
、また紘その一つを用いて、患者の生命を数都蔦ばすこ
とである0癌患者に通常行われるこれらoth療法があ
るKもかかわらず、癌患者全体03分の2は最終的に辷
の病気で死んでいる。
Those working in the technology field usually feel strongly that the genetic messages in carbonized cells can be reversed and the formation of cancer can be prevented. But to date, no means have been devised for carrying out such restorations. Therefore, the most commonly used and considered best cancer treatments are unpleasant, debilitating and sometimes disfiguring treatments, the triple combination of surgery, radiation and chemotherapy; Despite these treatments commonly given to cancer patients, two-thirds of all cancer patients eventually die from the disease. I'm here.

本発明が提供する癌の治療剤(癌治療用組成吻)は、大
抵の種lll0癌に効果があ)、癌のいずれの発達段階
にも有効であシ、また細胞の遺伝メツセージに直接作用
し、大量に入手できる豊富な原料物質から得られ、癌の
根治治療として役立つものである。
The cancer therapeutic agent (cancer therapeutic composition) provided by the present invention is effective against most types of cancer, is effective against any developmental stage of cancer, and has a direct effect on genetic messages in cells. It is obtained from abundant raw materials that are available in large quantities, and is useful as a radical treatment for cancer.

本発明はまた、あらゆる発達段階にある大多数のケース
の癌を有効に治療できる方法を提供する。
The present invention also provides methods that can effectively treat the majority of cases of cancer at all stages of development.

本発明を更に具体的に述べると、適当な一日服用量を4
s日から60日間、経口で患1tK投薬する方法によシ
、癌はいかなる発達段階にあっても治療されるOF、1
lot@in・)の;冒イドまた紘セ電プ冒イド懸濁液
かb威す、好ましくは免疫グ誼プリン(ガンマグ四プリ
ン)の#経口投薬と交互に投与する。
To describe the invention more specifically, an appropriate daily dose of 4
OF, 1, where cancer is treated at any stage of development by oral administration of 1tK for 60 days starting from day s.
lot@in.); or a suspension of the drug, preferably administered in alternation with an oral dose of immunogenic purine (gamma purine).

本発明は以下の特定具体例の詳細な説明より、十分に理
解されることと思われる。これらは単に実例として与え
られたものであ〕、これに@定するもので紘ないO 近年、生細胞の基礎特性は、細胞外の信号に答えて細胞
の遺伝子にスイッチを入れたり切りた砂する能力である
ことが研究された。例えば11人体ではすべての細胞(
赤血球Oようないくつかの種類の細胞を除く)は同一の
遺伝子セットをもつが、成長初期Ka遺伝子がスイッチ
の切換えによシ選択されるので、細胞は様々な形状と機
能を有している。
It is believed that the invention will be better understood from the detailed description of specific embodiments that follow. These are given merely as examples and are not intended to be conclusive.In recent years, the fundamental properties of living cells have been shown to be the ability of a cell's genes to be turned on or off in response to extracellular signals. It has been studied that it is the ability to For example, 11 In the human body, all cells (
Cells (with the exception of some types of cells such as red blood cells) have the same set of genes, but because the early-stage Ka gene is selected by flipping a switch, cells have different shapes and functions. .

バクテリアおよびウィルスにお砂る遺伝子制御の研究を
通じて、遺伝子制御の基本的メ′カニズム社、])1M
の長鎖状分子の特定部位1’Cあるたん白質分子の相互
作用に左右されることが、近年研究された。この相互作
用の結果として、遺伝子はスイッチを入れられた〉切ら
れ九りすゐ。最もよく理解された例では、遺伝子紘すプ
レッtH−制子:R・pバー−002という分子を制御
するヒとによシ、スイッチが切られ゛た。リプレッサー
の存在ti、1960年にパリのパスツール研究所Q?
7iauioisハsobと、raequ・−MO!l
eaによシ、初めて仮説として取上けられた。7午後1
(Wait・rGixb・rtが後を継ぎ、バーバード
大学で個別に働いてい九BennoMu41sr−H1
llとPtashneO協力を得て、リプレッサーをバ
クテリアから分離した◎ (Mar区I’ta@hn*
 、 Waiter Gllbert着[G・n・to
o l@pr・―・0ral 1970年6月刊を参照
)0その後、リプレッサーはオペレーターというDMム
の部位にしっかりと結びつけることができ、そのような
状−にするとリプレッサー紘オペレーターに隣接する遺
伝子がたん白質へ転写ならびに翻訳されるのを肪止する
ことが、明らかになりた。
Through research on gene regulation in bacteria and viruses, we have established Fundamental Mechanisms of Gene Regulation, Inc.]) 1M
In recent years, it has been studied that this depends on the interaction of a protein molecule at a specific site 1'C of a long-chain molecule. As a result of this interaction, the gene is switched on and off. In the best-understood example, the gene was turned off by a human controlling a molecule called pretH-regulated: Rp-002. The existence of repressors, 1960 at the Pasteur Institute Q?
7iauioisha sob and raequ・-MO! l
This is the first time that ea has been introduced as a hypothesis. 7 pm 1
(Wait・rGixb・rt succeeded him and worked individually at Barbard College. 9BennoMu41sr-H1
With the help of ll and PtashneO, we isolated the repressor from bacteria ◎ (Mar-ku I'ta@hn*
, Waiter Gllbert arrived [G・n・to
o l@pr --- 0ral (see June 1970 issue) 0Then, the repressor can be tightly linked to the part of the DM system called the operator, and in this way the gene adjacent to the repressor operator It has been revealed that this protein inhibits transcription and translation into proteins.

バク?97と同様に人間では、遺伝子はDMム分子Kl
jりた塩基配列と定義できる。I)liム分子社、二重
ラセンに巻かれ、水素結合によりて互いに連結され九ヌ
クレオチドの長い鎖2本で構成されている。各ヌクレオ
チド紘デオキシリボース糖、リン酸基および4つの窺素
埴基すなわちアデニン、グアニン、ラセン、シトシン(
略号紘ム、G%!、C)から成る@糖およりす。
Baku? Similarly to 97, in humans, the gene is the DM molecule Kl.
It can be defined as a unique base sequence. I) Lim Molecule Co., Ltd., is wound into a double helix and consists of two long chains of nine nucleotides connected to each other by hydrogen bonds. Each nucleotide has a deoxyribose sugar, a phosphate group and four diagonal groups, namely adenine, guanine, helical, and cytosine (
Abbreviation Hiromu, G%! , C) @sugar okarasu.

ン酸基は各鎖のバックボーンを形成し、塩基は二重ラセ
ンの中実軸へ伸びて、他O鎖から伸びた塩基と一対に1
にる・鎖に沿りえ塩基配列線補足的なものであ今。
The acid groups form the backbone of each chain, and the bases extend into the solid axis of the double helix, forming pairs with bases extending from other O chains.
This is a supplementary base sequence line along the chain.

ム紘つねにテと、0はつねにCとペアを組む◎DMムの
情報内容轄、塩基配列に↓如規定される。典臘的な遺伝
子は約1000の塩基ペアから威る◎遺伝子からたん白
質への翻訳は、酵素RMムポリメツ−ゼが塩基配列を[
メツセンジャーJ RNムの線形分子の補足配列へ1写
することがら開始される。リボゾームという細胞内翻訳
機械社メラセンジャー■ムに接着し、メッセンジャーR
NAの塩基配列をアミ)酸配列(連結されてたん白質分
子を形成している)へ翻訳する。
Muhiro always pairs with Te, and 0 always pairs with C. ◎ The information content of DM Mu is determined by the base sequence ↓. A typical gene consists of approximately 1,000 base pairs ◎ Translation from a gene to a protein is performed by the enzyme RM polymethase, which converts the base sequence into [
The transcription of the Metzenger JRN module into the complementary sequence of the linear molecule begins. Messenger R adheres to the intracellular translation machinery called the ribosome.
Translates the NA base sequence into an amino acid sequence (which is linked to form a protein molecule).

遺伝子からたん白質分子への翻訳は、複合遺伝子の数段
階の1つのとζろで抑制また紘妨害されることは明らか
であゐ@最近の研究では、抑制はDMム分子で直接性わ
れるので、遺伝子情報はリプレッサーが活性化している
限〉[メツセンジャーJItMムへ転写されないと断定
しえ。
It is clear that the translation of genes into protein molecules is suppressed or blocked by one of several steps in a complex gene. It can be concluded that genetic information is not transcribed into the Messenger JItM system as long as the repressor is activated.

リプレッサーは通例、DMムのレギ為レータ−と呼ばれ
る遺伝子によp発生する小サイズの酸性たん白質で、遺
伝子のオペレーターのプロモータ一部K11着してぃゐ
◎遺伝子線こうして、RMムポリメラーゼが前述グーモ
ータ一部に接着してメツ竜ンジャーR11Al集めるの
遺伝子の転写抑制の基本的メーニズムの概略を述べ□ て自九〇出願者は誘発IjIの組成内容の理論説明に縛
られ良くないが、癌は、細胞o*−を制御し、オペレー
ター遺伝子のリプレッサーとして作用する特定九ん白質
の合成をコード化する遺伝子のヌクレオチドeアデニン
、グアニン、チミンおよびシトシンの配列順序の化学的
な変化であると考えられているといわれる・この変化は
細胞の中の物理的、化学的または生物学的作因によって
起こシ、その変形を娘細胞へ遺伝として伝達する・リプ
レッサーを適切に合成できない娘細胞は、そこで細胞の
広範囲にわたる増殖をおこして異常組繊0@l) (初
期腫瘍)を形成し、塊シは他の器官へ転移してばらまか
れる。
Repressors are usually small acidic proteins produced by a gene called the DM regulator, which attaches to the K11 promoter of the gene's operator. The above-mentioned outline of the basic mechanism of transcriptional suppression of the gene by adhering to a part of the goomotor and collecting Metsuryonger R11Al has been described. Although the applicant is not bound by the theoretical explanation of the composition of the induced IjI, it is not good for cancer. is a chemical change in the sequence order of the nucleotides e adenine, guanine, thymine, and cytosine in the gene encoding the synthesis of a specific protein that controls cell o*- and acts as a repressor of the operator gene. It is said that this change is caused by physical, chemical, or biological factors within the cell, and the deformation is transmitted to daughter cells as genetics.Daughter cells that cannot properly synthesize the repressor are There, cells proliferate over a wide area to form an abnormal tissue 0@l) (initial tumor), and the mass metastasizes and spreads to other organs.

正常な細胞で紘、特定リプレッサーたん白質紘先に述べ
良ように、遺伝子オペレーターのプルモータ一部にある
I)Nムに付着し、RNムの発達と合成を制御する構造
遺伝子の転写を訪ける。
In normal cells, a specific repressor protein (Hiro) attaches to the I)N membrane located in the pull motor of the gene operator and visits the transcription of structural genes that control the development and synthesis of the RN membrane. Let's go.

これに対して細胞の細胞質にあシ、細胞INK付着して
いる特定し竜ブタ−たん白質がある。これら轄細胞間接
触に敏感で、組織の空白スペースをおそらく電磁気的変
化を通して記録する。これらのレセプター九ん白質が細
胞の核の方へ移動して、DMム、411にレギ轟レータ
ー遺伝子に付着し、生物の細胞集団を制御するりプレフ
サーたん白質の合成を行わず、細胞複製を誘発する。
On the other hand, there is a specific protein that is attached to the cell cytoplasm and is attached to the cell INK. These cells are sensitive to cell-cell contact and record empty spaces in the tissue, possibly through electromagnetic changes. These receptor proteins move toward the nucleus of the cell and attach to the regulator gene in the DM, 411, controlling the organism's cell population and inhibiting cell replication without the synthesis of prefusor proteins. provoke.

癌細胞紘、レギ為レーター遺伝子に起きる変化に左右さ
れるリプレッサーたん白質が変質して作用しないか、あ
るいはリプレッサー九ん白質を奪われた状態である。従
うて癌細胞はつねに、構造遺伝子が絶えず転写される状
態にあシ、その結果無限に複製が行われる。
In cancer cells, the repressor protein, which is influenced by changes in the regulator gene, is altered and does not function, or the repressor protein is deprived. Therefore, cancer cells are in a state where their structural genes are constantly being transcribed, resulting in endless replication.

細胞の癌に対する感受率は、細胞膜の透過性の増加によ
るとζろが大きい。この細胞膜の透過性が大きいと、癌
を進行させる物理的、作字的または生物学的作因がDI
ムに接触する可能性もふえるのである0ζうして、ある
種のホルモンが酵素触媒の速度に影響を及はし、細胞膜
O透過性を変化させる0このような情況は、キルセン刺
激をたえず受ける組織例え社哺乳動物の謙↑子官を癌に
#1lllシやすくさせる。
The susceptibility of a cell to cancer is greatly affected by the increased permeability of the cell membrane. If this cell membrane is highly permeable, physical, typographical, or biological factors that cause cancer to progress may become DI.
0ζThus, certain hormones can influence the rate of enzyme catalysis and alter cell membrane O permeability.This situation is particularly important for tissues that are constantly exposed to chilsen stimulation. For example, it makes the humble offspring of mammals more susceptible to cancer.

腫瘍を形成するウィルスの活動を!易にする因子となる
免疫能力の低下とともに、栄養不尼も細胞膜の透過性の
増加の一因である・ 生組織の全細胞の細胞質には、レセプターたん白質分子
が多数含まれていることも確かめられた。この九ん白質
はおそらく電磁気また紘電気化学的変化によシ発生し、
細胞が必要とされる隣接組織の空白スペースを探知しな
がら、細胞の核へと移行してDIムのレギ轟レーター遺
伝子に付着する@レギ為レーター遺伝子はそζでもはや
、オペレーター遺伝子のプW%−タ一部を封鎖するリプ
レッサー九ん白質を生産しなくなる。
The activity of viruses that form tumors! Malnutrition is also a contributing factor to increased cell membrane permeability, as well as decreased immune capacity, which is a contributing factor.The cytoplasm of all living tissue cells contains large numbers of receptor protein molecules. It was confirmed. This white matter is probably generated by electromagnetic or electrochemical changes,
As the cell searches for empty spaces in the adjacent tissue where it is needed, it migrates to the nucleus of the cell and attaches to the DI region's regulator gene. % - Stops producing repressor proteins that block part of the body.

従って、前述プルモータ一部は抑制から解放され、オペ
レーター遺伝子にメッセンジャーRNAの形成、および
組織の空白スペースを厘めるための細胞増殖を開始させ
る。この作用は、レセプター九ん白質が新しい細胞よっ
て満されたスペースを感知した場合に逆転する・このメ
カニイムによシ、必要なときだけ予め規定された細胞が
増、N1シ、増殖が生物に必要とされない場合は、休眠
状態にいる。
Thus, some of the pull motors are released from inhibition, allowing the operator genes to initiate messenger RNA formation and cell proliferation to fill the empty spaces in the tissue. This action is reversed when the receptors sense the space filled by new cells. This mechanism allows pre-defined cells to multiply only when needed, N1 cells, and proliferation required by the organism. If not, it remains dormant.

細胞−の透過性が増加すると、胞瘍を形成する外部作因
、主にウィルス性1)mlムは、前述細胞膜を透過し、
細胞の核へ移行してレギ孤し一一一遺伝子に永久に付着
する0これに千〕レギ瓢レーター遺伝子は適切なリプレ
ッサー九ん白質を生産しなくなる0従りて、リプレッサ
ーたん白質の欠除から細胞の絶えざる繁殖が開始され、
細胞は悪性になる0 そこで、組織に含まれるリプレッサーたん白質を患者に
投薬すれば、このリプレッサーたん白質は悪性細胞によ
り生産されなくなりた)プレフサーたん白質の代替物と
なって、オペレーター遺伝子のグーモータ一部に直接作
用し、オペレーター遺伝子が悪性細胞の絶えざる繁殖を
開始するのを防止することは、明らかである。
When cell permeability increases, external agents that form cysts, mainly viral 1) ml, can penetrate the cell membrane,
It migrates to the nucleus of the cell and becomes permanently attached to the repressor protein. This also causes the repressor gene to no longer produce the appropriate repressor protein. Continuous reproduction of cells begins from the deletion,
The cells become malignant. Therefore, if the repressor protein contained in the tissue is administered to the patient, this repressor protein becomes a substitute for the prefusor protein (which is no longer produced by the malignant cells), and the operator gene It is clear that it acts directly on the motor part and prevents the operator gene from starting the constant reproduction of malignant cells.

哺乳動物の神経組織が、個体の存命期間中決して増殖し
ない細胞の中に大量のリプレッサーたん白質を含有する
ことが発見され九〇これらのリプレッサーたん白質が患
者に投薬されると、胃腸管からリンパおよび血液系を通
つて、癌に犯された細胞へ這ばれる。1これらO癌細胞
の細胞膜透過性は著しく高くなってお〉、投薬されたリ
プレッサーたん白質は前述膜に浸透し、前述細胞のDM
ムオペレーター遺伝子のプロセータ一部に付着して、悪
性細胞のレギ為レーター遺伝子が生産しない正常リプレ
ッサー分子の代Boリプレッサー分子として作用する。
It has been discovered that the nervous tissue of mammals contains large amounts of repressor proteins in cells that never proliferate during the lifetime of the individual.90 When these repressor proteins are administered to a patient, they are from the lymphatic and blood systems to cancer-affected cells. 1 The cell membrane permeability of these cancer cells is extremely high, and the administered repressor protein penetrates the membrane and increases the DM of the cells.
It attaches to a portion of the promoter gene of the regulator gene of malignant cells and acts as a substitute Bo repressor molecule for the normal repressor molecule that is not produced by the regulator gene of malignant cells.

以上の理由から、哺乳動物の新鮮な神経組織、特に脳組
織から得られたDNA IJプッサーたん白質のコロイ
よシ形成され九m瘍を最終的に退縮、消滅させることが
発見されえ。
For the reasons mentioned above, it has been discovered that DNA obtained from fresh mammalian nervous tissue, especially brain tissue, can be formed in a colloid of IJ-pusser protein and ultimately cause the tumor to regress and disappear.

本発見の組成物によシ提供されるこの種のリプレッサー
九ん白質は、l1IlIII4内のみならず乳摩管なら
びに血管を通しても作用し、転移細胞を攻撃して、癌に
犯された患者の癌転移を阻止する。
This type of repressor protein provided by the composition of the present discovery acts not only within the 11IlIII4 but also through the mammary ducts and blood vessels to attack metastatic cells and cause cancer in cancer-affected patients. Prevent metastasis.

本発明に従い神経組織の組成物を調製するに妹、屠殺し
たばかシの哺乳動物の新鮮な神経組織をヨード水溶液(
1:2SGO)に約1〜3分間浸して前述組織の殺菌消
毒を行い、生きているバクテリアを九は他の病原菌が入
らないようにする。新鮮な組織を曹−ド液から取出し、
蒸留水で完全に洗浄して吸収した冒−素を洗い流す・そ
のあと前述組織をプレングーのようなもので1分間足ら
ず粉粋し、コルイドまた社セ電コロイド層濁箪を作る・
懸濁液社凍結状態で保存する0これは、薬理作用は懸濁
液の含有する完全無傷なたん白質によりて左右され、こ
のたん白質は高温に敏感なためである。
To prepare a neural tissue composition in accordance with the present invention, fresh neural tissue from a sacrificed mammal is injected into an aqueous iodine solution (
1:2 SGO) for about 1 to 3 minutes to sterilize and disinfect the tissue, removing living bacteria and preventing other pathogens from entering. Fresh tissue was removed from the soda solution,
Thoroughly wash the tissue with distilled water to wash away the absorbed proteins.Then, wash the tissue mentioned above with something like pre-goo for less than 1 minute to make a colloid layer.
The suspension is stored in a frozen state. This is because the pharmacological action depends on the intact protein contained in the suspension, and this protein is sensitive to high temperatures.

本発明の組成物を投薬するため、懸濁液を解凍して癌患
者に経口投与する。服用量状患者め腫瘍組1&1ftl
Fに対しO0S〜1omes服用期□間は4s〜60日
が望ましい◎その後顕著な退縮と最終治癒が、大部分の
ケースに観察された。
To administer the composition of the invention, the suspension is thawed and administered orally to a cancer patient. Dosage form patient tumor group 1 & 1 ftl
For F, the period of OOS to 1 omes □ is preferably 4s to 60 days ◎ Afterwards, significant regression and final healing were observed in most cases.

以下の例は、上記の癌治療法を適用した本発明の癌治療
剤(癌治療用組成物)の効力を例征している。
The following examples illustrate the efficacy of the cancer therapeutic agent (cancer therapeutic composition) of the present invention to which the above-described cancer therapeutic method is applied.

例1 哺乳動物の腺に腺癌を誘発するために、ノ1ムスター(
Hamst@r)20びきのグループに癌細胞が注射注
入された。癌は中間期まで進行させた。腺癌が選択され
た20び愈のハムスターすべてに十分に進行したとき、
屠殺して間も表い牛の脳組織を細分し殺菌消毒した組成
物を用いて10びきに治療を施した6服用量は24時間
K1mAを30日間、1日当たシ約5941 /ハムス
ターI輪に相当する。ハムスターの治療には、免疫グ四
プリン(ガン!グpグリン)は使用されなか−)良。
Example 1 In order to induce adenocarcinoma in mammalian glands, No. 1 muster (
Hamst@r) Cancer cells were injected into a group of 20 people. The cancer was allowed to progress to intermediate stage. When the adenocarcinoma was sufficiently advanced in all 20 selected hamsters,
6 doses of K1mA for 24 hours for 30 days, approximately 5941 ml per hamster I, were treated in 10 days using a composition prepared by sterilizing and sterilizing the brain tissue of cows that had just been slaughtered. Corresponds to a ring. Immune Guprin (Gan! Guppurin) is not used to treat hamsters.

治療用に選んだ10びきのハムスターは綿密に観察され
、治療開始からIts日目終わ如には、麹瘍組織が減少
し退縮した。治療の30日後には腺癌は完全に消滅し、
ハムスターの体重はツー増加し九。治療を施され九ハム
スター社30日後までに全部回復した。
The 10-year-old hamsters selected for treatment were closely observed, and at the end of its day after the start of treatment, the koji tumor tissue had decreased and regressed. Thirty days after treatment, the adenocarcinoma completely disappeared.
The hamster's weight increased by two and nine. After treatment, the patient made a full recovery within 30 days.

上記治療が朽われなかりた10びきのノ・ムスターも観
察された・1びきの例外なく全部が腫瘍の大きさを着し
く増し、生特性が失われ、体重は約2011減少し喪。
We also observed 10 cases of cancer that did not respond to the above treatment.In all cases, without exception, the size of the tumor steadily increased, the vital characteristics were lost, and the body weight decreased by about 2011cm.

これらのハムスターはすべて、その後90日以内一 痺死んだ。All of these hamsters were I died of paralysis.

例2 例10手順が繰返されたが、屠殺して間もない馬の脳組
織を使用した。得られた結果社例1と同じである0例3 完全発達し、種々の器官に転移し九癌患者30人の自発
志願グループに、次のように調合した組成物で処理を施
し九〇屠殺して間もない牛馬(小羊)の脳組織の一片を
l−ド液(1:25OO)K2分間浸した。殺菌消毒し
た組織を蒸留水で完全に洗浄し、そのあと1分間ワーリ
ング(Waring)ブレングーで粉粋シ、ヘビーシロ
ップの濃度にする。
Example 2 The procedure of Example 10 was repeated, but using freshly slaughtered horse brain tissue. The results obtained are the same as in Example 1. Case 3: A group of 30 volunteer patients with cancer that had fully developed and metastasized to various organs was treated with the composition prepared as follows and slaughtered for 90 days. A piece of fresh cow/horse (lamb) brain tissue was soaked in cold solution (1:25OO) for 2 minutes. The sterilized tissue is thoroughly washed with distilled water and then powdered in a Waring blender for 1 minute to a heavy syrup consistency.

選ばれた30人の患者は、次のように配分され九〇12
人の患者はピンクリスチンアドレアンシン(マ1nor
istin@adreamiains)とシクロフォス
ホアミド(Cyolophosphanids)を投薬
されて化学治療法を1回受けていた。他の15人の患者
はすでに2〜3回の化学治療法と数回の放射線治療法を
施されていた。残シの3人は多数の化学治療法と放射線
治療法をすでに受け、肝臓、肺、腎臓および腸のような
重要器官は非常に進行した癌に犯されていた。
The 30 selected patients were distributed as follows: 9012
Some patients are treated with pincristin adreensin (ma1nor).
He had undergone one round of chemotherapy, being prescribed istin@dreamiains) and cyclophosphoamides. The other 15 patients had already received two to three chemotherapy treatments and several radiation treatments. The remaining three had already undergone numerous chemotherapy and radiation treatments, and vital organs such as the liver, lungs, kidneys and intestines were affected by very advanced cancer.

患者30人は全員、上述組成物を1日服用量約1 mW
/腫瘍組織C1Fで投薬された(患者の各々につき服用
量は決められた)。また人間の免疫ンロブリン(ガンマ
グロブリン)を服用量72時間毎1(1mjを3運間非
経口で、あるいは馬の免疫グロブリン(ガンマグロブリ
ン)を24時間に1座薬(xomro座薬形M)で12
日間、患者をウィルス再感染から守る手段として投薬さ
れた。
All 30 patients received the above composition at a daily dose of approximately 1 mW.
/tumor tissue C1F (dose determined for each patient). Human immunoglobulin (gamma globulin) is administered parenterally every 72 hours (1 mj for 3 doses), or equine immunoglobulin (gamma globulin) is administered as a suppository (xomro suppository form M) for 12 hours every 24 hours.
The drug was administered for several days as a way to protect patients from reinfection with the virus.

また患者は全員、400mfのt1ルシウムリン酸塩の
丸薬を1日3回、ガンマグープリンの投薬期間中、投与
された。
All patients also received 400 mf t1 lucium phosphate pills three times a day during the gamma gopurin dosing period.

上記の治療から得られ元結果社、以下の過pである。The results obtained from the above treatment are as follows:

1回だけ化学療法を受けていた12人の患者社、腫瘍組
織が完全に消滅し、快癒の方向へ向かうた0治療終了後
1年間の管理のあと、腫瘍組織指示薬すなわち乳九〇前
述12人の患者で、#IIl!Fに管理し丸!年の間に
上記表示薬が増加する傾向を示す者社1人もいなかった
O すでに2〜3回の化学療法と数回の放射線療法を受は九
1s人の患者は、満足な治療結果が得られなかった・い
くつかのケースでは癌腫の量は減少したが、本治療によ
りて患者を完全に癌から救うこと社できなかりた0これ
らの患者は、上記治療後も化学および放射線療法を引続
き受は九が、満足する結果は得られなか癌に犯されてい
た3人の患者は、本発明による治療を受けたが、全員死
んボ。
The 12 patients who had received chemotherapy only once had their tumor tissue completely disappeared and were on their way to recovery. After one year of management after the completion of the treatment, a tumor tissue indicator, i.e. breast cancer, was administered to the 12 patients mentioned above. #IIl! Manage to F and circle! None of the 91 patients who had already received 2-3 rounds of chemotherapy and several rounds of radiotherapy had satisfactory treatment results. Although the amount of cancer decreased in some cases, this treatment did not completely save the patient from cancer.These patients will continue to receive chemotherapy and radiotherapy after the above treatment. Three patients suffering from cancer received treatment according to the present invention, but all of them died without satisfactory results.

以上杜、本治療は進行段階(ある限度内)およびそこK
t−*れる転移に関係なく、化学宜たは放射線療法を受
けなかり九癌に対してよシ効来があり、前述化学療法は
、患者の免疫学的応答を減らすことによシ患者はウィル
ス感染しやすくなることを示している。ウィルス感染は
、患者の細胞の遺伝子メツセージの変化によって、癌の
進行に非常に影替すると考えられている030ケースの
うち、12ケースだけが満足に治癒し、癌から完全に救
われた。これは、仁の例に述べたように行われた治療は
、牛馬の脳組織を用いることで、少くともケースの40
−に効果があることを意味しているO 例4 もう一つの自発的な20人の患者グループの10人は2
回以上の化学療法は受けておらず、放射線療法は全く受
けていない。他の10八拡化学、放射線療法と3と同様
の治療が施された0その結果、19人が完全に癌から救
済され、治療のあと1年間前述患者に行われた管理期間
、腫瘍組織の指示*a正常レベル以内であった。これは
、前述患者は癌から快癒したことを意味している。九だ
一人が操返し治療を受けなければならなかった。この患
者の腫瘍組織の退縮は、1回目の治療が施され九とき紘
はぼ満足できる結果が出九が、すべての癌細胞を完全に
防ぐには不十分で、しかもウィルス感染から腫瘍の発育
が復活した。これによシ上述と同じ2回目の治療が、患
者に施された。この患者は現在まで観察中で、+1ぼ満
足できる成行だが結果は1*はりt+シしない。
Above all, this treatment is suitable for advanced stages (within certain limits) and
Regardless of metastases, chemotherapy or radiotherapy is highly effective against nine cancers; This indicates that they are more susceptible to virus infection. Viral infection is thought to greatly influence cancer progression through changes in genetic messages in patients' cells.Of the 030 cases, only 12 cases were satisfactorily cured and were completely freed from cancer. This suggests that the treatment performed in Jin's case uses brain tissue from cows and horses, and in at least 40 cases.
- means that it has an effect on O Example 4 Another voluntary group of 20 patients, 10 of whom are 2
She has not received more than one round of chemotherapy and has not received any radiation therapy. Another 10 patients were treated with 8 extensive chemotherapy, radiotherapy and 3 similar treatments.As a result, 19 patients were completely rescued from cancer, and during the management period that was carried out on the aforementioned patients for 1 year after the treatment, tumor tissue was removed. Indication *a It was within the normal level. This means that the patient has successfully recovered from cancer. Only nine people had to undergo remedial treatment. The regression of this patient's tumor tissue was satisfactory after the first treatment, but it was not sufficient to completely prevent all cancer cells, and furthermore, the tumor growth caused by the viral infection. has been revived. The patient was then given a second treatment as described above. This patient has been under follow-up to date, and the outcome is +1+ satisfactory, but the results are 1*+t+.

このように、本例に従りて行われた治療は95−という
好結果を示した。
Thus, the treatment performed according to this example showed a good result of 95-.

上の例は、本発明の組成物の効力に関していくつかのヒ
ントを与えている。つtシ、ハムスター(H&mat@
r)に牛を九紘馬の脳組織で治療を施し九とき%100
9Gの成功率でありた。これに対し、人間にある種の牛
馬(小羊)とガンマグロブリンおよびカルタクムリン酸
塩で治療したときには、わずか40−のケースが完全に
満足のゆく結果と1做された。しかし、動物学的等級で
は人1[IK近い動物である霊長類の脳組織を用い九と
きには、軽減率社約95−に急増した。
The above examples give some hints as to the efficacy of the compositions of the invention. Tsutushi, hamster (H&mat@
r) Treatment of cows with Kuhiro horse brain tissue resulted in 9% 100%
The success rate was 9G. In contrast, when humans were treated with gamma globulin and cartacum phosphate, only 40 cases were considered completely satisfactory. However, when using the brain tissue of a primate, an animal close to human 1 [IK], the reduction rate rapidly increased to about 95.

上記の意味すゐところは、法的規定ならびに倫理的な障
害が取去られたら、おそらく人間の脳組織の使用dlG
o110成功を収めるということである。しかし人間O
i1組織を使りての実験社行われないだろう。と勤わけ
、人間の脳組織の経口摂取は倫理的に拒否されるであろ
うし、非経口で投薬するに社前述組織の凍結乾燥を行う
ことが必要だからである。
The implication of the above is that, once legal and ethical hurdles are removed, the use of human brain tissue would probably not be possible.
o110 It means achieving success. But human O
Experiments using the i1 organization will not be conducted. In particular, oral ingestion of human brain tissue would be ethically prohibited, and parenteral administration would require freeze-drying the tissue.

しかし、動物が人類に近いはと、その動物の脳組織の作
用は癌の進行緩和に効果があるというむとは、事実であ
る。
However, since animals are similar to humans, it is true that the effects of their brain tissue can be effective in mitigating the progression of cancer.

上記は明らかに、人類に近い動物種の脳組織に含まれる
リプレッサー九ん白質は、癌細胞の進行に犯されている
人間のリプレッサーによ〉類似したものであるという事
実による。ζOようKして、前述動物のリプレッサーた
ん白質は、癌細胞によシ損失または変化して亀は中生童
されてい危い前述リプレッサーたん白質の完壁な代替物
として作用する。
The above is apparently due to the fact that the repressor proteins contained in the brain tissues of species close to humans are similar to the repressors in humans that are affected by the development of cancer cells. As a result, the animal's repressor protein acts as a perfect substitute for the animal's repressor protein, which is at risk of being lost or altered by cancer cells, causing turtles to become unborn children.

本発明の組成物の投与法の概要を列挙すると次の通りで
ある。
The outline of the administration method for the composition of the present invention is as follows.

1、細分された哺乳動物の神経組織よシ得られた、DI
ムリプレッサー九ん白質O殺曹消11され九懸濁@02
、前述DMムリプレッナー九ん白質の懸濁液が、患者に
検出された悪性腫瘍組織の重さ1 mWに対し0.5か
らio mtである、前第1項による方法03、前述神
経組織が哺乳動物の脳組織である前第1項による方法0 4、前述哺乳動物の脳組織が牛科の脳組織である前第1
項によゐ方法。
1. DI obtained from subdivided mammalian nerve tissue
Muripressor White matter O sulfur quencher 11 and 9 suspension @ 02
, Method 03 according to the previous paragraph 1, wherein the suspension of the DM mulipreneurial white matter is 0.5 to io mt per 1 mW of the weight of the malignant tumor tissue detected in the patient; 4. Method 0 according to the preceding paragraph 1, in which the brain tissue of an animal is the brain tissue of a bovine.
How to do it depending on the section.

S、前述哺乳動物の脳組織が鳥科の脳組織である、前第
1項による方法。
S. The method according to the preceding paragraph 1, wherein the mammalian brain tissue is an avian brain tissue.

6、前述哺乳動物の脳組織が霊長類の脳組織である前濁
液が、哺乳動物の全脳組織の殺菌消毒されたコル濁液が
、凍結乾燥され九哺乳動物O全脳組織のコ四イド懸濁液
を含有する前第1項による方法。
6. The above-mentioned mammalian brain tissue is a presuspension of primate brain tissue, and the sterilized col suspension of mammalian whole brain tissue is freeze-dried. 1. The method according to the preceding paragraph containing an id suspension.

9、前述哺乳動物の脳組織が人間の脳組織である前第1
項による方法。
9. First, the mammalian brain tissue mentioned above is human brain tissue.
Method by term.

出願人  ダニエル マルバンードラー・トレ代通人伊
藤請之 同 横山吉美
Applicant Daniel Marvandler Torre representative Ueno Ito Yoshimi Yokoyama

Claims (1)

【特許請求の範囲】 (7) DMムリプレッサーたん白質が哺乳動物の神経
組織から得られ丸亀のである特許請求の範囲第、1項記
載の組成物。 口) 哺乳動物の神経組織が哺乳動物め脳組織である特
許請求OSm第2項記載O組成物。□ (2)哺乳動物O脳組織が牛科O脳組織である特許請求
の範囲第3項記載の組成物。□ 俤) 哺乳動物の脳組織が馬科の脳組織である特許請求
の範囲第3項記載の組成物6 俤) 鴫乳動物O脳組1が霊長ll0mg組織である特
許請求OSm第3項記載の組成物。 (η DMムリプレッサーたん白質が殺菌消毒され九懸
濁液であシ、哺乳動物の全一組織め一曹消壽されえコロ
イド懸濁液を含有する特許請求aIi@第3項記載の組
成物。 (2) DMムリプレッサーたん白質が、凍結乾燥され
た哺乳動物の全脳組lkのコロイド懸濁液である特許請
求の範囲第3項記載の組成物。 (呻 哺乳動物の脳組織が人間の脳組織である特許請求
の範囲第8項記載の組成物0
[Claims] (7) The composition according to claim 1, wherein the DM murepressor protein is obtained from mammalian nervous tissue and is produced by Marugame. 2. The composition according to claim 2, wherein the mammalian nervous tissue is mammalian brain tissue. (2) The composition according to claim 3, wherein the mammalian O brain tissue is bovine O brain tissue. □ 俤) Composition 6 according to claim 3, wherein the mammalian brain tissue is equine brain tissue 俤) Patent claim OSm according to claim 3, wherein the ocelot O brain group 1 is primate ll0mg tissue Composition of. (η) The composition according to claim 3, which contains a colloidal suspension in which the DM murepressor protein is sterilized and sterilized, and the whole tissue of a mammal is sterilized. (2) The composition according to claim 3, wherein the DM murepressor protein is a colloidal suspension of freeze-dried whole brain tissue of a mammal. Composition 0 according to claim 8, which is brain tissue of
JP56174406A 1980-05-01 1981-10-30 Composition for cancer treatment Pending JPS5874615A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14541980A 1980-05-01 1980-05-01

Publications (1)

Publication Number Publication Date
JPS5874615A true JPS5874615A (en) 1983-05-06

Family

ID=22513026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56174406A Pending JPS5874615A (en) 1980-05-01 1981-10-30 Composition for cancer treatment

Country Status (8)

Country Link
JP (1) JPS5874615A (en)
CA (1) CA1175741A (en)
CH (1) CH655659B (en)
DE (1) DE3116733A1 (en)
ES (1) ES8300477A1 (en)
FR (1) FR2481602A1 (en)
GB (1) GB2075988B (en)
MX (1) MX6826E (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2717227A (en) * 1954-12-22 1955-09-06 Helen L Dawson Composition containing nerve tissue extract and process of producing such extract
DE1095464B (en) * 1956-05-22 1960-12-22 Univ Tulane Method of making a remedy for treating schizophrenia and other mental illnesses

Also Published As

Publication number Publication date
CH655659B (en) 1986-05-15
FR2481602A1 (en) 1981-11-06
ES501835A0 (en) 1982-11-01
ES8300477A1 (en) 1982-11-01
GB2075988A (en) 1981-11-25
GB2075988B (en) 1983-09-01
DE3116733A1 (en) 1982-04-01
MX6826E (en) 1986-08-08
CA1175741A (en) 1984-10-09
FR2481602B1 (en) 1984-06-01

Similar Documents

Publication Publication Date Title
Kokaia et al. Brain insults in rats induce increased expression of the BDNF gene through differential use of multiple promoters
JPH03503633A (en) How genetic material is delivered to the blood-brain barrier
CN1107365A (en) A novel physiologically active substance
Schiff Central thalamic deep‐brain stimulation in the severely injured brain: rationale and proposed mechanisms of action
Hefti et al. Nerve growth factor and Alzheimer's disease
Sun et al. Reduction of hippocampal-kindled seizure activity in rats by stereotactic radiosurgery
AU2006343439B2 (en) The use of nicotine, analogues thereof, precursors thereof or derivatives thereof in the treatment of various pathological processes capable of improvement with a-MSH administered in prophylactic or therapeutic form
Christ et al. The application of gene therapy to the treatment of erectile dysfunction
Martins et al. Experimental delayed radiation necrosis of the brain: Part 1: Effect of early dexamethasone treatment
RU2099080C1 (en) Method for preventing from cancer development
Visted et al. Progress and challenges for cell encapsulation in brain tumour therapy
JPS5874615A (en) Composition for cancer treatment
CN115006423B (en) Application of tetrahedral framework nucleic acid in preparation of medicine for preventing and/or treating brain trauma sequelae
Connor Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides neuroprotection in the aged parkinsonian rat.
US20110165131A1 (en) Methods for treating diseases and increasing longevity
Son et al. Inhibition of γ-irradiation induced adhesion molecules and NO production by alginate in human endothelial cells
Callaway Improving neurologic outcomes after out-of-hospital cardiac arrest
Holmes et al. Consequences of cortical dysplasia during development in rats
CN112641796B (en) Nerve protection medicine for cerebral arterial thrombosis
US4559228A (en) Composition and method for the treatment of cancer
PL188157B1 (en) Drug for optimising mucus viscosity and stimulating intestinal functions
CN114288316B (en) Use of tetrahedral framework nucleic acid in preparation of medicine for treating pancreatitis
US4728511A (en) Composition and method for the treatment of cancer
AU3441793A (en) Enzyme castration of animals and tumor treatment
JPS62135431A (en) Bone marphozenic agent